Editorial
Lipoprotein (a): Is its systematic determination indicated?
Lipoproteína (a): ¿está indicada su determinación sistemática?
Manuel Antonio Botana López
Sección de Endocrinología, Hospital Universitario Lucus Augusti, Lugo, Spain
Read
10
Timeswas read the article
3
Total PDF
7
Total HTML
Share statistics
array:23 [ "pii" => "S253001802400060X" "issn" => "25300180" "doi" => "10.1016/j.endien.2024.02.005" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "1473" "copyright" => "SEEN and SED" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Endocrinol Diabetes Nutr. 2024;71:191-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2530016424000478" "issn" => "25300164" "doi" => "10.1016/j.endinu.2024.02.003" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "1473" "copyright" => "SEEN y SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Endocrinol Diabetes Nutr. 2024;71:191-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Lipoproteína (a): ¿está indicada su determinación sistemática?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "191" "paginaFinal" => "193" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Lipoprotein (a): Is its systematic determination indicated?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Manuel Antonio Botana López" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Manuel Antonio" "apellidos" => "Botana López" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S253001802400060X" "doi" => "10.1016/j.endien.2024.02.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S253001802400060X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016424000478?idApp=UINPBA00004N" "url" => "/25300164/0000007100000005/v1_202405080708/S2530016424000478/v1_202405080708/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2530018024000611" "issn" => "25300180" "doi" => "10.1016/j.endien.2024.02.006" "estado" => "S300" "fechaPublicacion" => "2024-05-01" "aid" => "1474" "copyright" => "SEEN and SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Endocrinol Diabetes Nutr. 2024;71:194-201" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Risk factors for hypoglycaemia in non-critical hospitalised diabetic patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "194" "paginaFinal" => "201" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Factores de riesgo de hipoglicemia en pacientes diabéticos hospitalizados no críticos: revisión sistemática de la literatura y metaanálisis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2829 "Ancho" => 2925 "Tamanyo" => 320416 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Forest plots of significant risk factors for hypoglycemia in non-critically ill hospitalized type 2 diabetic patients related to treatment.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Diego Valero Garzón, Santiago Forero Saldarriaga, Ana Milena Robayo Batancourt, José David Puerta Rojas, Valentina Aranguren Pardo, Lina Paola Fajardo Latorre, Milciades Ibañez Pinilla" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Diego" "apellidos" => "Valero Garzón" ] 1 => array:2 [ "nombre" => "Santiago" "apellidos" => "Forero Saldarriaga" ] 2 => array:2 [ "nombre" => "Ana Milena" "apellidos" => "Robayo Batancourt" ] 3 => array:2 [ "nombre" => "José David" "apellidos" => "Puerta Rojas" ] 4 => array:2 [ "nombre" => "Valentina" "apellidos" => "Aranguren Pardo" ] 5 => array:2 [ "nombre" => "Lina Paola" "apellidos" => "Fajardo Latorre" ] 6 => array:2 [ "nombre" => "Milciades" "apellidos" => "Ibañez Pinilla" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2530016424000600" "doi" => "10.1016/j.endinu.2024.02.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016424000600?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018024000611?idApp=UINPBA00004N" "url" => "/25300180/0000007100000005/v1_202406180529/S2530018024000611/v1_202406180529/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Lipoprotein (a): Is its systematic determination indicated?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "191" "paginaFinal" => "193" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Manuel Antonio Botana López" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Manuel Antonio" "apellidos" => "Botana López" "email" => array:1 [ 0 => "manuel.a.botana@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Sección de Endocrinología, Hospital Universitario Lucus Augusti, Lugo, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Lipoproteína (a): ¿está indicada su determinación sistemática?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The addition of highly potent hypolipidemic tools has allowed for significant reductions in cardiovascular risk (CVR). While apolipoprotein B (ApoB)-bearing proteins are primarily responsible for arteriosclerotic lesions, we can find residual CVR involving other contributing factors. Among these factors is lipoprotein (a) [Lp(a)]. Initial epidemiological studies, genome-wide association studies, and data from Mendelian randomization demonstrate a causal relationship between Lp(a) and ischemic heart disease,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> ischemic cerebrovascular disease, and aortic valve stenosis.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–4</span></a> Doubling the level of Lp(a) is associated with a nearly 20% increase in the risk of myocardial infarction, and elevated levels of Lp(a) are also associated with an accelerated progression of aortic stenosis.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Once a relationship was postulated between elevated levels of Lp(a) and an increased risk of venous thrombosis, which has not yet been confirmed5. However, an inverse relationship between the prevalence of lipoprotein(a) hyperlipoproteinemia and the incidence of type 2 diabetes does seem to be the case.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The Lp(a) molecule results from the fusion, through covalent bonds, of an ApoB particle with another apolipoprotein called apolipoprotein(a) [Apo(a)]. Both are synthesized in the liver, but it is yet to be elucidated whether their assembly occurs inside the hepatocyte or on its surface.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> By the structure of its gene (LPA), it is known that this is the result of the ancestral splitting of the plasminogen gene (PLG), with which it shares significant homology, which could help explain some of the pathophysiological characteristics of Lp(a).<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The PLG encodes 5 kringles (triple loop protein structures, 80–90 amino acids long, resembling the shape of a Scandinavian pastry and numbered from I to V), and a fibrinolytic protease region. LPA lacks kringles I to III, specific to PLG, but encodes 10 subtypes of kringle IV (KIV-1 to KIV-10) and a kringle V-like domain, as well as an inactive protease activity region. Apo(a) molecules and, consequently, Lp(a) molecules, exhibit considerable interindividual variability in their size and density, because the gene may have a highly variable number of copies of the kringle IV-2 subtype. Heterogeneity is also increased due to variable degrees of interindividual glycosylation.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–4</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">The larger the Apo(a) molecule, due to a greater number of kringle IV-2 copies, the lower its plasma levels. This heterogeneity explains between 20% and 70% of the variability in Lp(a) concentrations.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Additionally, single nucleotide polymorphisms also frequently influence concentration, unrelated to molecular size (more than 500 of these genetic variants of Lp(a) have been identified, some of which have significant effects on its concentration).<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Plasma levels of Lp(a) arise from the co-dominant expression of 2 LPA alleles, resulting in 2 detectable circulating Lp(a) isoforms of potentially different sizes, and the levels we measure correspond to the sum contributed by each allele.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> The smallest isoform tends to be present at higher levels. A threshold value of 50 mg/dL or 105 nmol/L (>80th percentile) has been established as clinically relevant, but even levels > 30 mg/dL can increase CVR.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6</span></a> The relationship between Lp(a) concentration and CVR is continuous, without a threshold: higher concentrations imply greater risk. Compared to individuals with mean Lp(a) concentrations of 16 nM, individuals with levels of 70, 115, 175, 230, and 350 nmol/L have 1.22, 1.40, 1.65, 1.95, and 2.72 times higher risk of developing arteriosclerotic vascular disease (ASVD), respectively.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> With Lp(a) concentrations >180 mg/dL (430 nmol/L), the CVR is that of familial hypercholesterolemia (FH).<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">The population distribution of Lp(a) is not normal, so the value ranges discussed are always in terms of "median" and not "arithmetic mean". Elevated concentrations are the most common form of hyperlipidemia. It is estimated that high Lp(a) affects between 10% and 30% of the world's population (approximately 1.42 × 109 people worldwide) and 20% of Europeans,<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,6</span></a> and having Lp(a) levels >100 nmol/L (48 mg/dL) accounts for 5.7% of all cardiovascular events reported.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Since more than 90% of Lp(a) concentration is conditioned by the LPA gene,<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,8</span></a> its values are reasonably constant throughout life, and therefore, a single determination might be enough. However, there is an individual variability of up to 20%,<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> and there are also non-genetic factors that can modify the concentration (inflammatory processes, chronic kidney disease, especially nephrotic syndrome, liver diseases, among others).<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,6,9</span></a> Therefore, sometimes it is recommended to obtain a mean of 2 Lp(a) determinations at different times, in stable phases of the patient's life, to refine CVR stratification.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,6</span></a> In any case, Lp(a) should be measure while the patient remains in a stable vital phase and without intercurrent illness.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Determining Lp(a) levels is achieved through immunoassays that use specific antibodies for Apo(a). However, there are 2 problems affecting the accuracy of the results and their clinical interpretation. The first one has to do Apo(a) size variability.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Due to an inverse association between the number of kringle IV-2 repeats and Lp(a) particle concentrations, polyclonal immunoassays that recognize epitopes in Apo(a) may tend to underestimate high Lp(a) concentrations and overestimate low concentrations depending on whether the isoforms are small or large, respectively.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> More recent methods commercially available reduce this error factor if the assay calibrators are well validated.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">The second problem is that there are 2 different approaches to immunoassay calibration, resulting in 2 different units for reporting Lp(a) results. The first highly sensitive analysis for measuring Lp(a) established results in mg/dL, while the current standard is calibrated in nmol/L.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Given the heterogeneity among the molecular sizes of different Lp(a) isoforms, determining their plasma levels expressed in mass units (mg/dL) may not be accurately representative of the number of particles we are actually measuring. This may be especially important when considering that each Lp(a) particle is 6 times more atherogenic than each ApoB.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Hence, recommendations for Lp(a) measurement indicate expressing its concentration in terms of molarity.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> The existence of two different units to express Lp(a) levels is confusing for physicians and patients alike, and there is no good conversion factor from mg/dL to nmol/L, or vice versa.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> In any case, whatever determination method is used, if properly calibrated, it allows us to identify patients with higher CVR due to elevated Lp(a) levels.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Measuring Lp(a) allows us to identify individuals with very high inherited plasma levels. It also enables better stratification of patients' CVR and improved management of cardiovascular disease by helping optimize the medical treatment of other CVR factors.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> In certain situations where Lp(a) is elevated, the LDL value should be corrected using the formula:<elsevierMultimedia ident="eq0005"></elsevierMultimedia><elsevierMultimedia ident="eq0010"></elsevierMultimedia></p><p id="par0055" class="elsevierStylePara elsevierViewall">This Lp(a) correction of the LDL value is not routinely recommended except for some situations: patients of sub-Saharan origin, patients with nephrotic syndrome or on peritoneal dialysis, or when the drop in LDL-C is insufficient after receiving lipid-lowering treatment.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Also, when FH is suspected, if correcting the LDL value can avoid the need for genetic diagnostic testing.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Since inheritance is autosomal, dependent on a single gene, detecting a case of hyperlipoproteinemia(a) allows us to cascade screening and initiate treatments at earlier ages if necessary.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> Regarding the spending associated with measuring Lp(a), considering that it would only need to be measured once in a lifetime, and the improvement it would represent in adjusting the treatment of CVR factors in people with elevated levels, it is expected to be efficient.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">The European Atherosclerosis Society (EAS) and individual cardiology societies from other countries (e.g., France, Germany, UK, Canada, Australia) have developed clinical practice guidelines that include recommendations for the population in which Lp(a) should be determined.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6,15–18</span></a> Although all recommend the routine measurement of Lp(a) in individuals with certain characteristics (elevated CVR, FH, first-degree relatives of individuals with very high Lp(a), family history of premature cardiovascular disease, calcified aortic stenosis, or when the LDL drop is not as expected after the established treatment), not all recommend measuring Lp(a) universally. This universal determination only appears in the guidelines of the EAS, the Spanish Society of Atherosclerosis, the German guidelines (which replicate those of the EAS), and the Canadian ones.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6,15,17</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">Since CVR is associated with elevated Lp(a), the efficiency of measuring it, and the currently available methodologies, the recommendations from the EAS are perfectly assumable and acceptable for our setting, and we would summarize them as follows<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>:</p><p id="par0075" class="elsevierStylePara elsevierViewall">• Lp(a) should be measured, at least, once in adults to identify those with high CVR.</p><p id="par0080" class="elsevierStylePara elsevierViewall">• Detection is also recommended in young people with a history of ischemic stroke or premature ASVD, or high Lp(a) and without other identifiable risk factors.</p><p id="par0085" class="elsevierStylePara elsevierViewall">• Cascade testing is recommended to detect high Lp(a) in FH environments, family history of high Lp(a), and personal or family history of ASVD.</p><span id="sec0041" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0101">Conflicts of interest</span><p id="par0095" class="elsevierStylePara elsevierViewall">None declared.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0041" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:5 [ "identificador" => "eq0005" "tipo" => "MULTIMEDIAFORMULA" "mostrarFloat" => false "mostrarDisplay" => true "Formula" => array:1 [ "Quimica" => "Lp(a) corrected by LDL cholesterol (LDL-C) (mg/dL) = LDL-C (mg/dL) − [Lp(a) (mg/dL) × 0.30]" ] ] 1 => array:5 [ "identificador" => "eq0010" "tipo" => "MULTIMEDIAFORMULA" "mostrarFloat" => false "mostrarDisplay" => true "Formula" => array:1 [ "Quimica" => "Lp(a) corrected by LDL cholesterol (LDL-C) (mmol/L) = LDL-C (mg/dL) − [Lp(a) (mg/dL) × 0.0078]" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:18 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W.C. Zheng" 1 => "W. Chan" 2 => "A. Dart" 3 => "J.A. Shaw" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ehjcvp/pvad074" "Revista" => array:7 [ "tituloSerie" => "Eur Heart J - Cardiovasc Pharmacother." "fecha" => "2024" "volumen" => "10" "numero" => "1" "paginaInicial" => "53" "paginaFinal" => "67" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37813820" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Vinci" 1 => "F.G. Di Girolamo" 2 => "E. Panizon" 3 => "L.M. Tosoni" 4 => "C. Cerrato" 5 => "F. Pellicori" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Environ Res Public Health." "fecha" => "2023" "volumen" => "20" "numero" => "18" "paginaInicial" => "6721" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relating Lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of 3 tests" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Szarek" 1 => "E. Reijnders" 2 => "J.W. Jukema" 3 => "D.L. Bhatt" 4 => "V.A. Bittner" 5 => "R. Diaz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.123.066398" "Revista" => array:7 [ "tituloSerie" => "Circulation." "fecha" => "2024" "volumen" => "149" "numero" => "3" "paginaInicial" => "192" "paginaFinal" => "203" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37632469" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the american heart association" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Reyes-Soffer" 1 => "H.N. Ginsberg" 2 => "L. Berglund" 3 => "P.B. Duell" 4 => "S.P. Heffron" 5 => "P.R. Kamstrup" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/ATV.0000000000000147" "Revista" => array:7 [ "tituloSerie" => "Arterioscler Thromb Vasc Biol." "fecha" => "2022" "volumen" => "42" "numero" => "1" "paginaInicial" => "e48" "paginaFinal" => "60" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34647487" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Kronenberg" 1 => "S. Mora" 2 => "E.S.G. Stroes" 3 => "B.A. Ference" 4 => "B.J. Arsenault" 5 => "L. Berglund" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehac361" "Revista" => array:7 [ "tituloSerie" => "Eur Heart J." "fecha" => "2022" "volumen" => "43" "numero" => "39" "paginaInicial" => "3925" "paginaFinal" => "3946" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36036785" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.L. Catapano" 1 => "M. Daccord" 2 => "E. Damato" 3 => "S.E. Humphries" 4 => "R.D.G. Neely" 5 => "B.G. Nordestgaard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.atherosclerosis.2022.02.013" "Revista" => array:6 [ "tituloSerie" => "Atherosclerosis." "fecha" => "2022" "volumen" => "349" "paginaInicial" => "136" "paginaFinal" => "143" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35292153" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Mach" 1 => "C. Baigent" 2 => "A.L. Catapano" 3 => "K.C. Koskinas" 4 => "M. Casula" 5 => "L. Badimon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehz455" "Revista" => array:7 [ "tituloSerie" => "Eur Heart J." "fecha" => "2020" "volumen" => "41" "numero" => "1" "paginaInicial" => "111" "paginaFinal" => "188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31504418" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the <span class="elsevierStyleItalic">LPA</span> gene" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Coassin" 1 => "F. Kronenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.atherosclerosis.2022.04.003" "Revista" => array:6 [ "tituloSerie" => "Atherosclerosis." "fecha" => "2022" "volumen" => "349" "paginaInicial" => "17" "paginaFinal" => "35" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35606073" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-genetic influences on lipoprotein(a) concentrations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Enkhmaa" 1 => "L. Berglund" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Atherosclerosis." "fecha" => "2022" "volumen" => "349" "paginaInicial" => "53" "paginaFinal" => "62" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Björnson" 1 => "M. Adiels" 2 => "M.R. Taskinen" 3 => "S. Burgess" 4 => "M.J. Chapman" 5 => "C.J. Packard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2023.10.039" "Revista" => array:7 [ "tituloSerie" => "J Am Coll Cardiol." "fecha" => "2024" "volumen" => "83" "numero" => "3" "paginaInicial" => "385" "paginaFinal" => "395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/38233012" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "First WHO/IFCC international reference reagent for Lipoprotein(a) for immunoassay--Lp(a) SRM 2B" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Working Group for Lipoprotein(a) Assay Standardization" "etal" => false "autores" => array:4 [ 0 => "F. Dati" 1 => "J.R. Tate" 2 => "S.M. Marcovina" 3 => "A. Steinmetz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Chem Lab Med" "fecha" => "2004" "volumen" => "42" "numero" => "6" "paginaInicial" => "670" "paginaFinal" => "676" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Arrobas Velilla" 1 => "C. Guijarro" 2 => "R. Campuzano Ruiz" 3 => "M. Rodríguez Piñero" 4 => "J.F. Valderrama Marcos" 5 => "A. Pérez Pérez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clínica Investig Arterioscler." "fecha" => "2023" "volumen" => "35" "numero" => "2" "paginaInicial" => "91" "paginaFinal" => "100" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Kronenberg" 1 => "S. Mora" 2 => "E.S.G. Stroes" 3 => "B.A. Ference" 4 => "B.J. Arsenault" 5 => "L. Berglund" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.atherosclerosis.2023.04.012" "Revista" => array:6 [ "tituloSerie" => "Atherosclerosis." "fecha" => "2023" "volumen" => "374" "paginaInicial" => "107" "paginaFinal" => "120" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37188555" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Saeed" 1 => "S.S. Virani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2741/4635" "Revista" => array:7 [ "tituloSerie" => "Front Biosci Landmark Ed." "fecha" => "2018" "volumen" => "23" "numero" => "6" "paginaInicial" => "1099" "paginaFinal" => "1112" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28930591" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.J. Pearson" 1 => "G. Thanassoulis" 2 => "T.J. Anderson" 3 => "A.R. Barry" 4 => "P. Couture" 5 => "N. Dayan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cjca.2021.03.016" "Revista" => array:7 [ "tituloSerie" => "Can J Cardiol." "fecha" => "2021" "volumen" => "37" "numero" => "8" "paginaInicial" => "1129" "paginaFinal" => "1150" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33781847" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HEART UK consensus statement on Lipoprotein(a): a call to action" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Cegla" 1 => "R.D.G. Neely" 2 => "M. France" 3 => "G. Ferns" 4 => "C.D. Byrne" 5 => "J. Halcox" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.atherosclerosis.2019.10.011" "Revista" => array:6 [ "tituloSerie" => "Atherosclerosis." "fecha" => "2019" "volumen" => "291" "paginaInicial" => "62" "paginaFinal" => "70" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31704552" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estándares SEA 2022 para el control global del riesgo cardiovascular" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Mostaza" 1 => "X. Pintó" 2 => "P. Armario" 3 => "L. Masana" 4 => "J.T. Real" 5 => "P. Valdivielso" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2021.11.003" "Revista" => array:7 [ "tituloSerie" => "Clín Investig Arterioscler" "fecha" => "2022" "volumen" => "34" "numero" => "3" "paginaInicial" => "130" "paginaFinal" => "179" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35090775" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Australian atherosclerosis society position statement on Lipoprotein(a): clinical and implementation recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.C. Ward" 1 => "G.F. Watts" 2 => "W. Bishop" 3 => "D. Colquhoun" 4 => "C. Hamilton-Craig" 5 => "D.L. Hare" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.hlc.2022.11.015" "Revista" => array:7 [ "tituloSerie" => "Heart Lung Circ." "fecha" => "2023" "volumen" => "32" "numero" => "3" "paginaInicial" => "287" "paginaFinal" => "296" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36707360" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25300180/0000007100000005/v1_202406180529/S253001802400060X/v1_202406180529/en/main.assets" "Apartado" => array:4 [ "identificador" => "64497" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25300180/0000007100000005/v1_202406180529/S253001802400060X/v1_202406180529/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S253001802400060X?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 3 | 9 |
| 2024 October | 1 | 0 | 1 |
